Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Nov 17;102(1):188–195. doi: 10.1038/sj.bjc.6605440

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2010 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Function of FGFR1-III isoform expression and p38-MAPK activity for SPARC expression. (A) SPARC expression in cells over-expressing FGFR1-IIIb and FGFR1-IIIc. The upper panels show representative SPARC immunoblot and PCR analyses in wild-type PANC-1 cells, PN5 and PN6 control-transfected, FGFR1-IIIb over-expressing PF4 and PF40, and FGFR1-IIIc over-expressing PFc18 and PFc51 cells. Densitometry of bands in relation to respective β-actin of three separate experiments is shown in the lower panel. The results are mean expression levels (±s.d.) in relation to wild-type PANC-1 (100%) of three separate experiments. ^*P<0.05 compared with wild-type and control-transfected cells. (B) SPARC expression in xenograft tumours. Immunohistochemical analysis of SPARC was performed in FGFR1-IIIb over-expressing (upper panel) and control-transfected (lower panel) tumours (Liu et al, 2007b). Representative areas from proliferating areas are shown. The arrow depicts the area of magnification of the inset. Bar=50 μm. (C) Glycosylation of SPARC. Incubation of FGFR1-IIIb over-expressing PF4 and wild-type PANC-1 cells with tunicamycin showed that SPARC protein was glycosylated. (D) Effects of the p38-MAPK inhibitor SB203580 and the JNK inhibitor SP600125 on endogenous SPARC expression in FGFR1-IIIb over-expressing PF4 and PF40 and wild-type PANC-1 cells. Indicated cells were incubated in the absence (−) and presence (+) of SB203580 (20 μM) or SP600125 (2 μM) for 24 h before analysis.